Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp increased its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 23.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 428,554 shares of the company’s stock after acquiring an additional 80,015 shares during the period. Bank of New York Mellon Corp owned approximately 0.29% of Xeris Biopharma worth $964,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of XERS. Invenomic Capital Management LP acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $1,336,000. Vanguard Group Inc. grew its holdings in Xeris Biopharma by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after buying an additional 519,897 shares in the last quarter. NEA Management Company LLC acquired a new stake in Xeris Biopharma in the 1st quarter valued at approximately $926,000. Rosalind Advisors Inc. raised its stake in Xeris Biopharma by 10.6% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company’s stock valued at $7,020,000 after acquiring an additional 300,000 shares in the last quarter. Finally, CenterBook Partners LP acquired a new position in Xeris Biopharma during the 4th quarter worth $260,000. 42.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Xeris Biopharma in a report on Thursday, August 15th.

Xeris Biopharma Trading Down 1.0 %

Shares of NASDAQ:XERS opened at $2.93 on Friday. The company has a 50 day moving average of $2.61 and a 200-day moving average of $2.26. The firm has a market cap of $434.39 million, a P/E ratio of -6.23 and a beta of 2.76. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.46 and a twelve month high of $3.26.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. The firm had revenue of $48.07 million during the quarter, compared to the consensus estimate of $46.80 million. During the same period in the prior year, the firm posted ($0.14) earnings per share. Equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.4 EPS for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.